Form 8-K - Current report:
SEC Accession No. 0001641172-25-015346
Filing Date
2025-06-17
Accepted
2025-06-17 08:30:11
Documents
15
Period of Report
2025-06-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 55696
2 EX-10.1 ex10-1.htm EX-10.1 78663
3 EX-10.2 ex10-2.htm EX-10.2 22152
  Complete submission text file 0001641172-25-015346.txt   391001

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20250616.xsd EX-101.SCH 3784
5 XBRL DEFINITION FILE lixt-20250616_def.xml EX-101.DEF 26650
6 XBRL LABEL FILE lixt-20250616_lab.xml EX-101.LAB 36768
7 XBRL PRESENTATION FILE lixt-20250616_pre.xml EX-101.PRE 25274
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5794
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 251051926
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)